At a Glance
| Detail | Ex Parte | Rescript |
|---|---|---|
| Category | Research & Analytics | Research & Analytics |
| Total raised | $7.5M | Not disclosed |
| Rounds tracked | 1 | Not disclosed |
| Latest round | Series A, $7.5M · Mar 2022 | Not disclosed |
| Last valuation | Not disclosed | Not disclosed |
| Lead investors | R8 Capital, Ironbound Partners | Not disclosed |
| Built for | Not disclosed | Not disclosed |
| Headquarters | US | Not disclosed |
Funding, Side by Side
Ex Parte rounds
- Mar 2022Series A$7.5M
Rescript rounds
No public rounds tracked yet.
Our Take
We have not tested these two head to head yet. The numbers above come from public funding announcements. If you use either one, tell us what you found and it may become a Field Note.
Quick Answers
- Which has raised more, Ex Parte or Rescript?
- Ex Parte has raised $7.5M in disclosed funding, compared with no disclosed amount for Rescript.
- What is Ex Parte best for?
- Litigation intelligence for patent and complex disputes.
- What is Rescript best for?
- Rescript helps legal and public policy teams research, track, and organize laws and policy across jurisdictions in one place.
Source: Legal Tech Circle funding data, from public announcements. Updated November 10, 2026.